Lucid Diagnostics issues 3.38M shares to parent PAVmed for services, expense reimbursement, and acquisition

Lucid Diagnostics Inc.

PAVmed elected stock for $1.65M in MSA fees (July-Sept 2022): 750,818 shares at 0.70 floor.
New PBERA formalizes expense reimbursement; PAVmed received 1,479,326 shares for $2.72M in accrued payroll/benefits.
CapNostics assignment settled with 1,145,086 shares to PAVmed, covering the ~$2.1M purchase price.
Total issuance of 3,375,230 unregistered shares to parent under Section 4(a)(2) exemptions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.